Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer

Inclusion criteria

* Patient Population Type: Advanced Muscle Invasive Bladder Cancer * Prior Therapy: One prior therapy for advanced disease * Disease: Measurable disease * ECOG Performance: 0,1 * Indication: Histologically Proven Carcinoma of the bladder * For female patient of childbearing potential, neither pregnant nor breastfeeding, and under active contraception * Allergies: No known allergy to one of the study drugs * Patient Status: * No CNS metastases * No peripheral neuropathy \> grade1 * No other serious concomitant illness * Fully recovered from any prior therapy * Informed Consent: Patient and doctor have signed informed consent * Lower Age Limit: Lower age limit \>18 * Upper Age Limit: Upper Age Limit \<70 * ANC: ANC \>1500/mm3 or WBC \> 3000/mm3 * Platelets: Platelets \>100,000/mm3 * Creatinine: Creatinine \<1.8mg/dL * Bilirubin: Bilirubin \<=2.0 x ULN * SGPT: SGPT (ALT) \<=1.5 x ULN (\<4xULN if liver metastases present) * RBC: Hemoglobin \> 9.0g/dL * Cardiovascular: No active congestive heart failure, no uncontrolled angina, no myocardial infarction within the past 6 months * Patients with metastatic cancer of the urothelial tract (TCC, Adenocarcinoma) * No prior exposure to Oxaliplatin * No cytotoxics or radiation 4 weeks prior to enrolling on protocol * PT/PTT normal